Amgen (AMGN) Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.

15 brokers have issued twelve-month price targets for Amgen's stock. Their AMGN share price forecasts range from $200.00 to $320.00. On average, they predict the company's stock price to reach $265.44 in the next twelve months. This suggests that the stock has a possible downside of 0.3%.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

Amgen's stock was trading at $262.64 at the beginning of the year. Since then, AMGN shares have increased by 1.4% and is now trading at $266.28.
View the best growth stocks for 2023 here.

Amgen saw a drop in short interest in August. As of August 31st, there was short interest totaling 6,200,000 shares, a drop of 11.8% from the August 15th total of 7,030,000 shares. Based on an average daily volume of 2,520,000 shares, the days-to-cover ratio is currently 2.5 days. Approximately 1.2% of the company's stock are sold short.
View Amgen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AMGN earnings forecast.

Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Thursday, August, 3rd. The medical research company reported $5.00 earnings per share for the quarter, beating analysts' consensus estimates of $4.44 by $0.56. The medical research company had revenue of $7 billion for the quarter, compared to the consensus estimate of $6.66 billion. Amgen had a net margin of 30.02% and a trailing twelve-month return on equity of 196.60%. Amgen's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $4.65 EPS.
Read the conference call transcript.

Amgen declared a quarterly dividend on Tuesday, August 1st. Investors of record on Friday, August 18th will be paid a dividend of $2.13 per share on Friday, September 8th. This represents a $8.52 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for AMGN.

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), FT Cboe Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD).

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.18%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 57.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.77% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

Amgen updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $17.80-$18.80 for the period, compared to the consensus earnings per share estimate of $17.73. The company issued revenue guidance of $26.6-$27.4 billion, compared to the consensus revenue estimate of $27.02 billion.

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by many different institutional and retail investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (57.86%), BlackRock Inc. (8.78%), State Street Corp (5.44%), Geode Capital Management LLC (2.21%), Charles Schwab Investment Management Inc. (2.10%) and Capital Research Global Investors (1.79%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMGN stock can currently be purchased for approximately $266.28.

Amgen (NASDAQ:AMGN) has a market capitalization of $142.43 billion and generates $26.32 billion in revenue each year. The medical research company earns $6.55 billion in net income (profit) each year or $14.83 on an earnings per share basis.

The company employs 25,200 workers across the globe.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.